The size of the Protein A Resins Market in the Asia Pacific was worth USD 94.37 million in 2021. This value is further estimated to be growing at a CAGR of 9.3% and worth USD 147.21 million by 2026. The market is showcasing evident potential during the forecast period owing to increasing research on monoclonal antibodies, which is anticipated to drive the sales of Protein A resins.
Protein A resins can be used to obtain high degrees of purification. This is because antibodies bind protein A ligands to the resins preferentially. During the forecast period, this is likely to increase demand for protein A resins in Asia. In addition, rising monoclonal antibody research activity, growth in the number of monoclonal antibodies in development, and essential players supplying innovative protein Next-generation protein, components involved for the protein include a resin for conducting clinical studies are all factors expanding the market significantly. In the purification of monoclonal antibodies, chromatography is a crucial step (mAbs).
Over the last decade, the need for monoclonal antibodies has skyrocketed in cancer and numerous other therapeutic areas, including neurological, autoimmune, and inflammatory diseases. As a result, nearly all major pharmaceutical firms concentrate their research and development efforts on therapeutic antibodies. Anionic contaminants such as nucleic acids and endotoxins are removed by chromatography during the purification of monoclonal antibodies. This technique uses many resins in drug development since it's used for more than just purification. It's also used to examine the ionic interactions of compounds. Size-exclusion chromatography is used to extract impurities like albumin and transferrin (SEC).
Protein A resins are 5-10 times more expensive than other resin kinds. Despite the fact that no other technology can attain purification levels as high as protein A resins, their exorbitant cost forces end-users to seek alternatives. The cost of protein A resin is projected to drop considerably when new industry participants enter the market. As minor market entrants provide resins at significantly lower prices while maintaining equivalent product quality, the rising pressure on prominent industry participants will likely result in price reductions.
This research report on the APAC Protein A Resins market has been segmented and sub-segmented into the following categories:
By Product Type:
By Application:
By Matrix Type:
By End Users:
By Country:
Geographically, the APAC region holds the largest share of the global market during the forecast period due to the growing usage of protein A resins in drug development, technological improvements, and an increase in the number of life sciences research activities in the region.
Due to a well-established pharmaceutical sector and increased R&D investment to develop novel and advanced medicines, the Japanese protein resins market held the most significant share of the APAC market in 2020.
The Chinese protein A resins market growth is expected to be aided by a growing focus on advancing monoclonal antibody applications in the nation. Over the forecast period, a growing emphasis on research and development and an increase in the number of pharmaceutical and biotechnology companies are estimated to drive the market size. In addition, antibodies, particularly monoclonal antibodies, are being more widely used for medicinal and diagnostic purposes, which might drive up demand for antibody purification products.
Emerging economies like India and China and industrialized economies like Japan have increased their R&D spending for the treatment of rare and autoimmune diseases.
KEY MARKET PLAYERS:
Companies dominating the APAC Protein A Resins Market profiled in this report are GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific, and EMD Millipore and Expedeon Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product Type
5.1.1 Natural Protein A Resin
5.1.2 Recombinant Protein A Resin
5.2 By Application
5.2.1 Immunoprecipitation
5.2.2 Antibody Purification
5.3 By End Users
5.3.1 Biopharmaceutical Manufacturers
5.3.2 Clinical Research Laboratories
5.3.3 Academic Institutes
5.4 By Matrix Type
5.4.1 Glass or Silica
5.4.2 Agarose
5.4.3 Organic Polymer
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Thermo Fisher Scientific
8.3 Repligen
8.4 Tosoh Bioscience
8.5 EMD Millipore
8.6 Novasep
8.7 GenScript
8.8 Expedeon Ltd
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
